• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Scientific Advisory Board
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us
    • Careers

Celyad to Present Data at 24th Congress of the European Hematology Association

May 16, 2019 By Celyad

Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced the selection of three abstracts for poster presentation at the upcoming 24th Congress of the European Hematology Association (EHA) in Amsterdam, The Netherlands, on June 13-16, 2019, including updated data from the THINK and DEPLETHINK Phase 1 trials evaluating the company’s autologous NKG2D-based CAR-T therapy CYAD-01 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndrome (MDS).

Clinical Presentation

Title:          Updated Results from the Phase 1 Trials Assessing a NKG2D CAR T-Cell Approach in Relapsed/Refractory Acute Myeloid Leukimia and Myelodysplastic Syndrome Patients. Download the poster 

Abstract:    PS1212

Session:     Gene therapy, cellular immunotherapy and vaccination – Clinical

Date:         Saturday, June 15th

Time:         5:30 – 7:00 p.m. CEST (Poster Area)

Preclinical Presentations

Title:          Development of a Next Generation Allogeneic CAR-T Cell Platform Without Gene Editing. Download the poster.

Abstract:    PS1210

Session:     Gene therapy, cellular immunotherapy and vaccination – Biology & Translational   Research

Date:          Saturday, June 15th

Elevator pitch:   4:30 – 4:45 p.m. CEST (Hall G106)

Time:          5:30 – 7:00 p.m. CEST (Poster Area)

Title:           Modeling NKG2D-based CAR-T Cell Therapy in Animals with Acute Myeloid Leukemia. Download the poster

Abstract:     PS974

Session:      Acute myeloid leukemia – Biology & Translational Research

Date:          Saturday, June 15th

Time:          5:30 – 7:00 p.m. CEST (Poster Area)

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Corporate, Non-regulated

Footer

  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use

Our website uses cookies including analytics cookies to help improve it by collecting statistics on how visitors use our website. By clicking on "I accept", you allow us to place these analytics cookies. We also use cookies that are necessary for the good functioning of our website. You can find out more information about the cookies we use by visiting our Cookie Policy. I acceptI refuseCookie Policy